Article Sidebar
Views pdf: 42
DESCRIBING 2 CASES OF PROSTATE CANCER WITH BRCA2 GENE MUTATION
Main Article Content
Abstract
Prostate cancer is a common male cancer and ranks fifth in cancer-related mortality among men worldwide. Germline mutations in the BRCA2 gene are particularly associated with a high risk of Prostate cancer, and adverse outcomes in treatment, and clinical. Additionally, BRCA2 gene mutations are one of the selected criteria for PARP (Poly ADP ribose polymerase) inhibitors treatment in cases of metastatic castration-resistant Prostate cancer. The study describes the clinical characteristics, progression, and genetic counseling of two prostate cancer cases with germline variants at positions c.8364G>A and c.2612C>G in the BRCA2 gene. These variants were detected by next-generation sequencing and direct Sanger sequencing.
Article Details
Keywords
Prostate cancer, gene BRCA2
References
2. Junejo NN, AlKhateeb SS. BRCA2 gene mutation and prostate cancer risk. Saudi Med J. 2020;41(1):9-17. doi:10.15537/smj.2020.1.24759
3. Schaeffer EM, Srinivas S, Adra N, et al. NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023: Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2022;20(12):1288-1298. doi: 10.6004/jnccn.2022.0063
4. Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology. 2020;31(9): 1119-1134. doi:10.1016/ j.annonc.2020.06.011
5. Castro E, Goh C, Olmos D, et al. Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer. J Clin Oncol. 2013;31(14): 1748-1757. doi:10.1200 /JCO.2012.43.1882
6. Castro E, Romero-Laorden N, del Pozo A, et al. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. JCO. 2019;37(6):490-503. doi:10.1200/JCO.18.00358